MedPath

A multi-centre double blind randomised controlled trial of aspirin and/or folate supplementation for the prevention of recurrent colorectal adenomas

Not Applicable
Completed
Conditions
Cancer
Recurrent colorectal adenomas
Malignant neoplasm of rectosigmoid junction
Registration Number
ISRCTN22669537
Lead Sponsor
Cancer Research UK (CRUK) (UK)
Brief Summary

2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18022173

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
1000
Inclusion Criteria

Eligible patients who have had:
1. Removal of adenomas greater than 0.5 cm after fixation or adenomas greater than 0.7 cm at the time of removal, within the last six months
2. A previous history of removal of such adenomas and have had adenoma of any size removed in the six months prior to recruitment These adenomas will be histologically confirmed and removed by either colonoscopy, flexi-sigmoidoscopy or via Transanal Endoscopic Microsurgery (TEMS) procedure

Exclusion Criteria

1. Over 75 years at time of recruitment
2. Serious medical conditions likely to preclude successful completion of the trial
3. Existing use of prescribed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) including aspirin
4. Known aspirin intolerance or sensitivity
5. Active bleeding disorders or upper Gastrointestinal (GI) ulceration, including use of anticoagulants
6. Previous resection of the large bowel

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of patients who developed one or more recurrent colorectal adenomas or cancers
Secondary Outcome Measures
NameTimeMethod
1. Number of recurrent adenomas detected during follow-up<br>2. Percentage of patients who developed advanced colorectal neoplasia during follow-up
© Copyright 2025. All Rights Reserved by MedPath